Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
作者信息
Agostinetto Elisa, de Azambuja Evandro, Lambertini Matteo
机构信息
Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.
Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
出版信息
NPJ Breast Cancer. 2023 Mar 16;9(1):14. doi: 10.1038/s41523-023-00515-4.
Abstract
摘要
相似文献
1
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.回复：预测模型低估了HER2阳性早期乳腺癌患者的生存率。
NPJ Breast Cancer. 2023 Mar 16;9(1):14. doi: 10.1038/s41523-023-00515-4.
2
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.提出的事项：PREDICT低估了HER2阳性早期乳腺癌患者的生存率。
NPJ Breast Cancer. 2023 Mar 16;9(1):13. doi: 10.1038/s41523-023-00514-5.
3
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.多变量预后评分指导早期 HER2 阳性乳腺癌的全身治疗：一项回顾性研究及外部评估。
Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2.
4
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.由雌激素受体/孕激素受体/人表皮生长因子受体2亚型定义的乳腺癌生存率以及根据肿瘤分级和免疫组化生物标志物的替代分类
J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26.
5
Optimal treatment of early stage HER2-positive breast cancer.早期 HER2 阳性乳腺癌的最佳治疗方法。
Cancer. 2018 Dec 1;124(23):4455-4466. doi: 10.1002/cncr.31657. Epub 2018 Oct 6.
6
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.用于预测早期HER2阳性乳腺癌病理反应和生存结果的新型HER2DX检测方法的开发与验证
EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.
7
Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.根据分子亚型，年轻女性局限性早期乳腺癌放疗后的生存情况。
Cancer Med. 2019 Jun;8(6):2840-2857. doi: 10.1002/cam4.2186. Epub 2019 Apr 23.
8
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.辅助拉帕替尼治疗早期 HER2 阳性乳腺癌的随机对照 3 期临床试验。
Lancet Oncol. 2013 Jan;14(1):88-96. doi: 10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10.
9
Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.联合雌激素受体和孕激素受体水平可预测人表皮生长因子受体 2 阳性早期乳腺癌的生存结局。
Clin Breast Cancer. 2022 Feb;22(2):e147-e156. doi: 10.1016/j.clbc.2021.05.012. Epub 2021 Jun 16.
10
Survival-Associated Metabolic Genes and Risk Scoring System in HER2-Positive Breast Cancer.HER2 阳性乳腺癌中与生存相关的代谢基因和风险评分系统。
Front Endocrinol (Lausanne). 2022 May 19;13:813306. doi: 10.3389/fendo.2022.813306. eCollection 2022.
本文引用的文献
1
Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.提出的事项：PREDICT低估了HER2阳性早期乳腺癌患者的生存率。
NPJ Breast Cancer. 2023 Mar 16;9(1):13. doi: 10.1038/s41523-023-00514-5.
2
HER2-Low Breast Cancer: Where Are We?HER2低表达乳腺癌：我们目前的进展如何？
Breast Care (Basel). 2022 Dec;17(6):533-545. doi: 10.1159/000527391. Epub 2022 Oct 6.
3
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.PREDICT低估了HER2阳性早期乳腺癌患者的生存率。
NPJ Breast Cancer. 2022 Jul 20;8(1):87. doi: 10.1038/s41523-022-00452-8.
4
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.早期乳腺癌辅助内分泌和化疗的生物标志物：ASCO 指南更新。
J Clin Oncol. 2022 Jun 1;40(16):1816-1837. doi: 10.1200/JCO.22.00069. Epub 2022 Apr 19.
5
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.用于预测早期HER2阳性乳腺癌病理反应和生存结果的新型HER2DX检测方法的开发与验证
EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.
6
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort.低激素受体阳性乳腺癌患者的预后：一项基于 15 年人群的队列分析。
Ann Oncol. 2021 Nov;32(11):1410-1424. doi: 10.1016/j.annonc.2021.08.1988. Epub 2021 Aug 20.
7
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).国际 III 期 ALTTO 试验（BIG 2-06/Alliance N063D）的更新结果。
Eur J Cancer. 2021 May;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Epub 2021 Mar 23.
8
Clinical utility of genomic signatures in young breast cancer patients: a systematic review.年轻乳腺癌患者基因特征的临床应用：一项系统评价
NPJ Breast Cancer. 2020 Sep 25;6:46. doi: 10.1038/s41523-020-00188-3. eCollection 2020.
9
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.青春期后癌症患者的生育力保存及治疗后妊娠：ESMO临床实践指南
Ann Oncol. 2020 Dec;31(12):1664-1678. doi: 10.1016/j.annonc.2020.09.006. Epub 2020 Sep 22.
10
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.分析激素受体状态对人表皮生长因子受体 2（HER2）阳性早期乳腺癌患者的影响：来自随机临床试验 ALTTO（BIG 2-06）的探索性分析。
Breast Cancer Res Treat. 2019 Aug;177(1):103-114. doi: 10.1007/s10549-019-05284-y. Epub 2019 May 27.
Zotero 插件